1. Introduction {#sec1-vetsci-06-00092}
===============

In chickens, neoplastic diseases typically have a viral etiology and cause a significant economic impact \[[@B1-vetsci-06-00092],[@B2-vetsci-06-00092],[@B3-vetsci-06-00092]\]. The three primary disease-causing agents are the Marek's disease virus (MDV), the avian leukosis virus (ALV), and the reticuloendotheliosis virus (REV). The prototype MDV is the Gallid alphaherpesvirus 2 (serotype 1, MDV1) and is grouped in the Mardivirus genus together with the following relative strains: The Gallid alphaherpesvirus 3 (serotype 2, MDV2) and Meleagrid alphaherpesvirus (serotype 3, MDV3), according to the latest information released on the Herpesviridae family at the International Committee on Taxonomy of Viruses (ICTV) \[[@B4-vetsci-06-00092]\].

Infections caused by MDV1 are associated with lymphoproliferative lesions, which can include nervous affection, paralysis, bursal atrophy, parenchymal neoplastic cellular infiltrations, pleomorphic lymphomas, and neoplastic cells infiltration in several visceral organs, nerves, muscles, and the skin \[[@B5-vetsci-06-00092]\]. Pathotypic classification for MDV designates the following 4 groups: mild (mMDV), virulent (vMDV), very virulent (vvMDV), and very virulent plus (vv+MDV) \[[@B1-vetsci-06-00092]\].

ALV is an Alpharetrovirus, and it is the most representative species of this genus. Strain classification of ALV that infects chickens includes six subgroups (A--J), which are classified according to the antigenicity of the viral envelope glycoproteins; depending on the group, the virus can cause lymphoid or myeloid leukosis. Tumors are usually nodular, and infiltrations are composed of uniform neoplastic infiltrations of lymphoblasts \[[@B2-vetsci-06-00092]\].

REV is a Gammaretrovirus that is associated with runting-stunting syndrome, neoplasia of lymphoid and other tissues, acute reticulum cell neoplasia, and immunodepression \[[@B3-vetsci-06-00092]\]. All known reported REV strains are strongly related serologically, but they are divided into subtypes 1 (REV1, prototype REV-T), 2 (REV2, prototype Spleen Necrosis Virus (SNV)), and 3 (REV3, prototype Chicken Syncytial Virus (CSV)) \[[@B6-vetsci-06-00092]\].

The classical methods for the differential diagnosis of lymphoid neoplastic diseases in birds are viral isolation and histopathological examinations; however, due to the technical difficulties of the virus isolation and the absence of pathognomonic microscopic lesions, molecular or immunohistochemical tests are often required \[[@B5-vetsci-06-00092]\]. Usually, diagnostic and research laboratories process and may store tissues for several years. Because of this storage practice, techniques have been developed to perform PCR for oncogenic viruses \[[@B7-vetsci-06-00092],[@B8-vetsci-06-00092]\].

Coinfection and the integration of the partial or total genome of REV into other avian viruses, such as MDV \[[@B9-vetsci-06-00092],[@B10-vetsci-06-00092]\] and fowlpox (FPV) \[[@B11-vetsci-06-00092],[@B12-vetsci-06-00092]\] virus, were discovered several years ago. These mutagenesis events can alter the biological functions of the viruses involved, including field strains or even vaccine strains \[[@B13-vetsci-06-00092],[@B14-vetsci-06-00092],[@B15-vetsci-06-00092]\]. The presence of MDV worldwide, primarily in countries with a poultry industry, is detected and generally controlled with the use of commercial vaccines \[[@B1-vetsci-06-00092]\]. On the other hand, reports of REV infections are much less common and ubiquitous in field samples.

Brazilian backyard flocks are usually not vaccinated against most of the avian viruses and even isolated cases of disease are not properly communicated. In South America, antibodies against REV have been detected alone in Peru by ELISA test \[[@B16-vetsci-06-00092]\] or in coinfection with MDV in Argentina by Agar gel precipitation (AGP) tests and fluorescent antibodies assays \[[@B17-vetsci-06-00092]\]. However, these reports did not provide molecular characterization of these viruses.

The present study reports for the first time in Brazil the presence of REV in coinfection with MDV in a clinical case. In addition, this study presents the first molecular characterization of REV in South America.

2. Materials and Methods {#sec2-vetsci-06-00092}
========================

2.1. Clinical History, Gross Lesions, and Histopathologic Examination {#sec2dot1-vetsci-06-00092}
---------------------------------------------------------------------

A retrospective study was designed to clarify a case (USP386) that corresponds to samples of a twelve-week-old domestic hen from a backyard chicken flock located in São Paulo State in 2010. This flock consisted of 40 birds not vaccinated against MDV and the clinical symptoms observed in the farm were apathy, loss of appetite, and facial cyanosis. Four birds died 3 days after detecting the symptoms and were discarded by the farmer. Approximately half of the flock began to show the same symptoms, and the hen referred was taken to the School of Veterinary Medicine (USP) for necropsy. Gross lesions examination highlighted regular body condition (weight of bird---1.08 kg), marked splenomegaly and hepatomegaly with multifocal to coalescing white foci and diffuse white areas ([Figure 1](#vetsci-06-00092-f001){ref-type="fig"}a,b); dark lungs; diffuse thickening of proventricular and small intestine mucosa wall; bilateral increased thickness of peripheral nerves. Samples of liver, spleen, kidney, lung, trachea, proventriculus, gizzard, small intestine, peripheral nerves, and ganglion were fixed in 10% formalin, embedded in paraffin, cut into 5-µm sections, and stained with hematoxylin and eosin (H&E) for light microscopic examination. Otherwise, samples of liver, spleen, proventriculus, and small intestine were frozen at −80 °C since 2010.

2.2. Detection of MDV and REV Viruses through PCR Examination {#sec2dot2-vetsci-06-00092}
-------------------------------------------------------------

Commercial vaccines (CVI988/Rispens, SB-1, and HVT) were used as positive controls for the MDV serotypes and synthetic DNA fragments (Invitrogen™ GeneArt™ Strings™) in the case of REV and ALV. Spleen from specific-pathogen-free (SPF) chicken resuspended in 1.5 mL of phosphate-buffered saline (PBS) was used as a negative control. DNA extraction of the controls and samples of liver, spleen, proventriculus, and small intestine were performed using the DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) according to the manufacturer's specifications. The eluted suspensions were quantified with a NanoDrop One (ThermoFisher Scientific, Carlsbad, CA, USA) and stored at −80 °C for the subsequent PCR procedures. PCR methods for the detection of MDV and REV were performed as described previously ([Table 1](#vetsci-06-00092-t001){ref-type="table"}) \[[@B8-vetsci-06-00092]\]. An RT-Nested-PCR reaction for the detection of ALV was performed as previously described ([Table 1](#vetsci-06-00092-t001){ref-type="table"}) \[[@B18-vetsci-06-00092]\].

2.3. Real-Time PCR to Detect and Differentiate CVI988 from the Field MDV Serotype {#sec2dot3-vetsci-06-00092}
---------------------------------------------------------------------------------

To rule out the presence of the MDV1 type vaccine (CVI988), two SYBR Green based real-time PCR tests (Fast SYBR™ Green Master Mix, Applied biosystems, Austin, TX, USA) were performed on all samples, which tested positive for MDV detection in [Section 2.2](#sec2dot2-vetsci-06-00092){ref-type="sec"} with thermal conditions according to a previously described method, which targets a single nucleotide polymorphism (SNP) of nucleotide 320 in the pp38 gene \[[@B19-vetsci-06-00092]\]. The non-CVI988 reaction uses the Non-CVI988-F and the MDV pp38-R primers ([Table 1](#vetsci-06-00092-t001){ref-type="table"}) and is specific for amplification of MDV1 strains different of CVI988. The CVI988 specific reaction uses the CVI988-F and the MDV pp38-R primers ([Table 1](#vetsci-06-00092-t001){ref-type="table"}) and is specific for amplification of the Rispens vaccine.

2.4. PCR Amplification of the Glycoprotein B Gene of the MDV Serotypes {#sec2dot4-vetsci-06-00092}
----------------------------------------------------------------------

To confirm the MDV serotype by sequencing, a PCR method was developed using generic primers ([Table 1](#vetsci-06-00092-t001){ref-type="table"}) to amplify a fragment of glycoprotein B (gB) that is common to all three MDV serotypes (MDV-1: Gallid herpesvirus 2, MDV-2: Gallid herpesvirus 3, MDV-3: Meleagrid herpesvirus 1), using the reference sequences (NC_002229, NC_002577, and NC_002641, respectively). The volume of the reaction mix was 25 µL, including 50 ng of template DNA, 0.2 mM of each dNTP, 2 mM MgCl~2~, 0.5 µM of each primer, 1× PCR buffer, and 1 U of Platinum *Taq* DNA Polymerase (ThermoFisher Scientific, Carlsbad, CA, USA). The thermal conditions included an initial denaturation step at 94 °C for 3 min, followed by 35 cycles of 94 °C for 60 s, 54 °C for 60 s, and 72 °C for 90 s, followed by a final elongation step at 72 °C for 10 min.

2.5. PCR for the Gag, Polymerase, and Envelope Genes of REV {#sec2dot5-vetsci-06-00092}
-----------------------------------------------------------

To confirm the integrity of the REV provirus in the positive samples, two PCRs were developed to amplify fragments of the *gag* + polymerase (*pol*) and envelope (*env*) genes ([Table 1](#vetsci-06-00092-t001){ref-type="table"}), according to the REV sequences of the complete genomes that are available at the GenBank ([Table 2](#vetsci-06-00092-t002){ref-type="table"}). In both cases, a 25 µL PCR was performed, including 50 ng of template DNA, 0.2 mM of each dNTP, 2 mM MgCl~2~, 0.6 µM of each primer, 1× PCR buffer, and 0.75 U of Platinum *Taq* DNA Polymerase (Thermo Fisher Scientific, Carlsbad, CA, USA). The thermal conditions included an initial denaturation step at 94 °C for 3 min, followed by 35 cycles of 94 °C for 45 s, 60 °C for 45 s, and 72 °C for 90 s, followed by a final elongation step at 72 °C for 10 min.

2.6. Sequencing and Phylogenetic Analysis {#sec2dot6-vetsci-06-00092}
-----------------------------------------

The PCR product of gB, *gag* + *pol*, and *env* from the respective positive control (MDV vaccines) and the sample with the highest concentration were purified with the IllustraTM GFX PCR and Gel Band Purification Kit (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) according to the manufacturer's instructions. Sequencing was performed on an ABI 3730 DNA Analyzer with the BigDyeTM Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Thermo Fisher Scientific, Carlsbad, CA, USA). The sequencing products were assembled using Geneious Prime^®^ 2019.0.4. ([www.geneious.com](www.geneious.com)).

The sequences of glycoprotein B from the MDV samples and vaccines were analyzed together with other previously published MDV sequences ([Table 3](#vetsci-06-00092-t003){ref-type="table"}). Partial REV sequences corresponding to the *pol* and *env* genes were analyzed and compared with the reference sequences ([Table 2](#vetsci-06-00092-t002){ref-type="table"}). Multiple sequence alignments were performed using Clustal W \[[@B20-vetsci-06-00092]\], and an identity matrix of nucleotides and inferred amino acids was generated using Geneious Prime^®^ 2019.0.4. The selection of the best-fit substitution models and the construction of phylogenetic trees were performed using MEGA v7.0 \[[@B21-vetsci-06-00092]\].

The sequence data generated in this study was submitted to the GenBank with the following accession numbers: USP386-MDV (MH825642), CVI988 (MH825643), SB-1 (MH825644), HVT (MH825645), and USP386-REV (*gag* + *pol*: MH673475; *env*: MH673476).

3. Results {#sec3-vetsci-06-00092}
==========

3.1. Histopathologic Examination {#sec3dot1-vetsci-06-00092}
--------------------------------

Marked uniform small to medium size neoplastic lymphocytes were infiltrating and replacing multifocal to diffuse the liver and spleen parenchyma ([Figure 2](#vetsci-06-00092-f002){ref-type="fig"}a,b). There were multifocal neoplastic lymphoid cells in the kidney and lung. Trachea, proventriculus, gizzard, and small intestine lamina propria showed increased thickness by uniform neoplastic lymphocytes infiltration. Peripheral nerves and ganglion were moderate to marked infiltrated by uniform neoplastic lymphocytes, as showed in [Figure 2](#vetsci-06-00092-f002){ref-type="fig"}c,d, respectively. There were few heterophils and plasma cells among neoplastic lymphocytes in all organs examined. Thymic atrophy also was observed in part and there were lymphocytes arranged in focal nodules.

3.2. Detection of MDV, REV and ALV through PCR examination {#sec3dot2-vetsci-06-00092}
----------------------------------------------------------

A PCR product of 226 bp corresponding to a fragment of the pp38 gene was detected in all four DNA samples analyzed (liver, spleen, proventriculus, and small intestine) and the positive control. Generic PCR for the gB gene tested positive and amplified a fragment of 728 bp in all the samples and the positive controls for 3 MDV serotypes. According to real-time PCR analysis, Cycle threshold (Ct) values for the non-CVI988 reaction were 19.28 in liver, 18.70 in spleen, 25.58 in proventriculus, 22.72 in small intestine, and undetermined for Rispens vaccine and for negative control. For CVI988-specific reaction, all the organ samples and the negative control did not amplify (Ct values undetermined) while for Rispens vaccine the Ct value was 10.88.

In the case of REV, a PCR product of 201 bp corresponding to a fragment of LTR was detected in all four DNA samples analyzed as well as the positive synthetic control. PCRs designed to amplify the junction between the *gag* + *pol* genes and the last part of the *env* gene tested positive and amplified fragments of 767 and 703 bp, respectively, in all organ samples. All MDV positive controls tested negative in all REV-specific PCRs. The RT-Nested-PCR reactions for ALV were negative for all the organ samples and positive in the synthetic control.

3.3. Sequence and Phylogenetic Analysis {#sec3dot3-vetsci-06-00092}
---------------------------------------

The similarity analysis between the USP386 MDV sequence with respect to the reference sequences grouped by serotype showed the highest similarity with the MDV1 serotype at the nucleotide level (99.8--100%) and at the amino acids level (100%) ([Table 4](#vetsci-06-00092-t004){ref-type="table"}). The phylogenetic analysis showed that the sequence corresponding to USP386 MDV (MH825642) was found in the cluster corresponding to the MDV1 serotype and the positive control of the same serotype (vaccine Rispens, MH825643). Similarly, the positive controls of serotype 2 (vaccine SB-1, MH825644) and serotype 3 (vaccine HVT, MH825645) were grouped in the corresponding clusters with 100% bootstrap support in all cases ([Figure 3](#vetsci-06-00092-f003){ref-type="fig"}). The analysis of similarity in the case of the *pol* gene of REV for the sample USP386 showed greater similarity with the subtype REV3 at the nucleotide level (99.5--100%) as well as at the amino acid level (98.9--100%). Similarly, the *env* gene analysis revealed greater similarity with the REV3 subtype at the nucleotide level (99.2--100%) as well as at the amino acid level (98.5--100%) ([Table 5](#vetsci-06-00092-t005){ref-type="table"}). The phylogenetic analysis for the REV *pol* gene ([Figure 4](#vetsci-06-00092-f004){ref-type="fig"}) showed that the grouping of the sequence corresponded to the USP386 sample within the REV3 subtype. Likewise, in the case of the *env* gene ([Figure 5](#vetsci-06-00092-f005){ref-type="fig"}), the sample USP386 was grouped within the subtype REV3.

4. Discussion {#sec4-vetsci-06-00092}
=============

The coinfection of MDV and REV in the field case of lymphoma was described for the first time in Brazil. The histopathological findings correspond primarily to Marek's disease characterized by neoplastic small to medium size lymphocytes infiltrations in several visceral organs as described previously \[[@B1-vetsci-06-00092],[@B5-vetsci-06-00092]\]. In addition to these lesions, enlargement of the spleen and liver is a frequent finding in cases of MDV infection with increased mortality and have already been reported in cases of coinfection of MDV with REV \[[@B9-vetsci-06-00092],[@B13-vetsci-06-00092],[@B15-vetsci-06-00092]\] as well as with another avian viruses \[[@B22-vetsci-06-00092],[@B23-vetsci-06-00092],[@B24-vetsci-06-00092]\]. All organ samples tested positive in the PCRs for the pp38 and gB MDV genes and the LTR, *gag*, *pol*, and *env* REV genes, indicating the coinfection in all samples examined. Real-time PCR assays based on the SNP of nucleotide 320 in the pp38 gene \[[@B19-vetsci-06-00092]\] were used to differentiate the field strains from the Rispens vaccine (CVI988). In this process, the possibility of infection by the MDV1 serotype vaccine was excluded. To further exclude the presence of the MDV2 and MDV3 serotypes, a generic PCR based on the gB gene was designed, as this gene is one of the most conserved genes among the three serotypes, including the field and vaccine strains \[[@B25-vetsci-06-00092],[@B26-vetsci-06-00092],[@B27-vetsci-06-00092],[@B28-vetsci-06-00092],[@B29-vetsci-06-00092],[@B30-vetsci-06-00092],[@B31-vetsci-06-00092]\]. Sequencing demonstrated high levels of identity in the amino acid comparison of the gB gene among the three serotypes, and a lower identity in the comparison of nucleotides. A higher level of discrimination at the nucleotide level among the three serotypes was demonstrated in the phylogenetic tree, with bootstrap supports of 100% for each serotype. Thus, this gB fragment can be used for differential diagnosis and molecular typing. The detection of the REV LTR, *gag* + *pol*, and *env* genes suggests that REV was present with the total proviral genome. REV presents a highly conserved genome \[[@B9-vetsci-06-00092],[@B32-vetsci-06-00092],[@B33-vetsci-06-00092],[@B34-vetsci-06-00092],[@B35-vetsci-06-00092],[@B36-vetsci-06-00092]\]. The USP386 REV strain reflects this fact and shows a high percentage of identity in nucleotides and amino acids for the two genes evaluated. Based on the analysis of both genes, there was greater identity with the strains of the REV3 subtype, intermediate identity with REV1, and lower identity with REV2.

In the phylogenetic analysis of the *pol* gene, the Brazilian REV (USP386) was grouped in subtype 3 (REV3) and was shown to be more closely related to strains 104865 (KJ56349), CY1111 (KJ909531), 1105 (JQ804915), and APC-566 (DQ387450). In the phylogenetic analysis of the *env* gene, USP386 was also grouped in the REV3 subtype and was shown to be more closely related to strains 104865 (KJ56349) and APC-566 (DQ387450). The phylogenetic distribution for both genes is consistent with previous reports \[[@B9-vetsci-06-00092],[@B37-vetsci-06-00092],[@B38-vetsci-06-00092]\]. It has been shown that there is no correlation between time, place, or specific host in the distribution of REV; however, most of the strains reported, including the present study, belong to the REV3 subtype \[[@B39-vetsci-06-00092],[@B40-vetsci-06-00092],[@B41-vetsci-06-00092]\]. The occurrence of cases caused only by REV is infrequent. However, the origin and distribution of these viruses are complex and can be influenced by several factors, including the contamination of vaccines with MDV \[[@B42-vetsci-06-00092]\], FPV \[[@B43-vetsci-06-00092],[@B44-vetsci-06-00092]\], IBDV \[[@B34-vetsci-06-00092]\], biological products, or free-living birds \[[@B39-vetsci-06-00092],[@B45-vetsci-06-00092],[@B46-vetsci-06-00092]\]. REV can remain undetected for a long time while it is transmitted horizontally through the direct contact of birds or through certain insects \[[@B47-vetsci-06-00092]\], integrated into other field viruses \[[@B9-vetsci-06-00092],[@B10-vetsci-06-00092],[@B11-vetsci-06-00092],[@B12-vetsci-06-00092],[@B48-vetsci-06-00092]\], or transmitted vertically by eggs \[[@B49-vetsci-06-00092]\]. Additionally, REV has no specific host or specific geographic location, having been detected in chickens, ducks, turkeys, geese, pheasants, Japanese quails, peafowl, guinea fowls, and Attwater's prairie chickens in several countries and continents \[[@B3-vetsci-06-00092]\]. Particularly, in the case of South America, two serological reports in Peru \[[@B16-vetsci-06-00092]\] and Argentina \[[@B17-vetsci-06-00092]\] indicated the presumable presence of REV in this region several years ago. However, it will be difficult to determine the source of REV in Brazil until further studies of regional strains are available. The immunosuppressive capacity of REV can significantly influence poultry farming, leading to economic losses associated with reduced efficiency, morbidity, and increased mortality from coinfections with other pathological agents, which can be associated exclusively with the damages. The genome status of REV (partial or integral) in coinfection with other field viruses can lead to alterations in the severity of lesions \[[@B10-vetsci-06-00092],[@B13-vetsci-06-00092],[@B14-vetsci-06-00092]\] and the inefficiency of vaccines \[[@B9-vetsci-06-00092],[@B15-vetsci-06-00092],[@B50-vetsci-06-00092]\].

As reports of the MDV strain in Brazil are scarce, even more in backyard chicken flocks, this study remembers the importance of the vigilance. On the other hand, the apparition of MDV in backyard flocks is a common event \[[@B51-vetsci-06-00092]\] with the presence of low and high-virulence pathotypes \[[@B52-vetsci-06-00092],[@B53-vetsci-06-00092]\]. The pathogenicity of the MDV strain detected in this study could be comparable with the highest virulent ones, based on the percentage of mortality (\>10%) and the lymphoproliferative lesions observed in necropsy ([Figure 1](#vetsci-06-00092-f001){ref-type="fig"}a,b) and histopathologic examination ([Figure 2](#vetsci-06-00092-f002){ref-type="fig"}a--d). Some possibilities arise here, a virulent enough MDV strain could be responsible for the typical clinic manifestations without the participation of REV; or the last could be helping to a less virulent MDV strain to cause the pathogenic effects. However, conclusive evidences about this should be supported by different approaches as experimental infections and additional genomic studies.

5. Conclusions {#sec5-vetsci-06-00092}
==============

The knowledge of the infective process and pathologies associated with REV is not fully clarified despite having spent many years since its first reports and studies in some countries with developed poultry industry. In fact, it is possible that this virus is circulating in several other countries, but its monitoring can be neglected. In this context, the South American region includes several countries with notable development of the poultry industry, as is the case of Brazil. Despite the "rumors" about some isolated cases of REV in this continent, this study represents the first description of REV with molecular characterization and in coinfection with MDV causing oncogenic manifestation. However, the main limitation of this study was the number of samples. Further studies involving more cases and samples could reveal or discard the presence of these viruses on field nowadays. We believe that the presence of REV in this region represents a serious threat to many avian species due to its wide spectrum of target hosts and may include not only commercial birds but also ornamental birds, pets, and free-living birds.

Due to the absence of a vaccine or treatment against REV, it is very important to ascertain its origin through monitoring so that measures for eradication and prevention must be taken. In addition, Marek's disease is associated with large economic losses in poultry and can be supplied with pathogenic viruses from the backyard chicken flocks as the presented strain.

Finally, the importance of this study highlights the REV and MDV detection into this region and provide molecular clues for future research about these viruses.
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![Gross, hen, 12-weeks-old. Multifocal to coalescing white foci associated with (**a**) marked enlarged liver, (**b**) marked enlarged spleen.](vetsci-06-00092-g001){#vetsci-06-00092-f001}

![Marek's disease and reticuloendotheliosis in histopathology with hematoxylin and eosin (H&E) stanning. (**a**) Liver: Proliferation and infiltration of neoplastic small to medium size lymphocytes that replaced liver parenchyma. The neoplastic cells were uniform and small lymphocytes. (**b**) Spleen: Neoplastic lymphoid cells expanding and obliterating histologic structures; and with a highlight in detail of lymphocytes. (**c**) Ganglion: Neoplastic uniform small lymphocytes infiltration and hemorrhage foci. (**d**) Peripheric nerve. Increased cellularity due to small lymphocytes infiltration.](vetsci-06-00092-g002){#vetsci-06-00092-f002}

![Phylogenetic analysis of the nucleotide sequences of the MDV strains based on the partial gB gene. The strain names and GenBank accession numbers are shown. The black circle represents the field MDV strain used in this study. The black rhombus represents the MDV vaccinal control strains. The phylogenetic tree was constructed in MEGA v7.0 using the Neighbor-Joining method with 1000 bootstrap replicates. The evolutionary distances were computed using the Kimura 2-parameter model (K2 + G + I), and the scale bar represents the number of base substitutions per site.](vetsci-06-00092-g003){#vetsci-06-00092-f003}

![Phylogenetic analysis of the nucleotide sequences of the REV strains based on the partial *pol* gene. The strain names and GenBank accession numbers are shown. The black circle represents the field REV strain used in this study. The phylogenetic tree was constructed in MEGA v7.0 using the Neighbor-Joining method with 1000 bootstrap replicates. The evolutionary distances were computed using the Kimura 2-parameter model (K2), and the scale bar represents the number of base substitutions per site.](vetsci-06-00092-g004){#vetsci-06-00092-f004}

![Phylogenetic analysis of the nucleotide sequences of the REV strains based on the partial *env* gene. The strain names and GenBank accession numbers are shown. The black circle represents the field REV strain used in this study. The phylogenetic tree was constructed in MEGA v7.0 using the Neighbor-Joining method with 1000 bootstrap replicates. The evolutionary distances were computed using the Kimura 2-parameter model (K2), and the scale bar represents the number of base substitutions per site.](vetsci-06-00092-g005){#vetsci-06-00092-f005}

vetsci-06-00092-t001_Table 1

###### 

Detailed list of the primers used in this study.

  ------------------------------------------------------------------------------------------------------------------------------------------------
  Primer Designation   Primers Sequence                        Target Gene   Location \*               Size Product   Reference
  -------------------- --------------------------------------- ------------- ------------------------- -------------- ----------------------------
  MdCv-F\              5′-GTGATGGGAAGGCGATAGAA-3′\             pp38          127525--127506 ^A^\       226 bp         \[[@B8-vetsci-06-00092]\]
  MdCv-R               5′-TCCGCATATGTTCCTCCTTC-3′                            127300--127319 ^A^                       

  SNV-LTR-F\           5′-AATGGTTGTAAAGGGCAGAT-3'\             LTR (REV)     267-286/8012--8031 ^B^\   201 bp         \[[@B8-vetsci-06-00092]\]
  SNV-LTR-R            5'-CTCCTCTCACTGCCAATCT-3′                             466--448/8211--8193 ^B^                  

  Leu3.2F\             5′-GGAAATGTAGTGTTATRCRATACTCTTATG-3′\   LTR (ALV)     7514--7543 ^C^\           321 bp         \[[@B18-vetsci-06-00092]\]
  Leu7R                5′-ATCCGCTTCATGCAGGTGCTC-3′                           7813--7834 ^C^                           

  Leu11F\              5′-CGTCGATTGGTGGAAGTAAGGTGG-3′\         LTR (ALV)     7594--7617 ^C^\           213 bp         \[[@B18-vetsci-06-00092]\]
  Leu12R               5′-TCA GGG AAT CGA CGG TCC GGC C-3′                   7785--7806 ^C^                           

  CVI988-F\            5′-GAGGGAGAGTGGCTGTCAAG-3′\             pp38          127487--127468 ^A^\       188 bp         \[[@B19-vetsci-06-00092]\]
  Non-CVI988-F\        5′-GAGGGAGAGTGGCTGTCAAA-3′\                           127487--127468 ^A^\                      
  MDV pp38-R           5′-TCCGCATATGTTCCTCCTTC-3′                            127300--127319 ^A^                       

  MDVgB-gF1\           5′-CCCATRCCGTTRAACAATTC-3′\             gB            61554--61573 ^A^\         728 bp         This study
  MDVgB-gR1            5′-GTYCAATTCGCCATGCTCCA-3′                            62281--62262 ^A^                         

  REV-Pol1-F5\         5′-ACTCGCCCAGGAGAGTAGAG-3′\             gag + pol     2269--2288 ^B^\           767 bp         This study
  REV-Pol1-R5          5′-GAATAGTTTCGCGCAGGCTT-3′                            3035--3016 ^B^                           

  REV-Env3-F12\        5′-GTGCATACTGGCATCAATCG-3′\             env           7050--7069 ^B^\           703 bp         This study
  REV-Env3-R12         5′-CCACATTCCCCACYGCTCTT-3′                            7752--7733 ^B^                           
  ------------------------------------------------------------------------------------------------------------------------------------------------

\* According to reference genomes for ^A^: MDV (NC_002229), ^B^: REV (NC_006934) and ^C^: ALV (Z46390).

vetsci-06-00092-t002_Table 2

###### 

Reference reticuloendotheliosis virus (REV) strains used for the phylogenetic analysis.

  Strain Designation   Isolation Year   Source         Country   GenBank Accession Numbers
  -------------------- ---------------- -------------- --------- ---------------------------
  SNV                  1959             Duck           USA       DQ003591
  ATCC-VR775           1972             Duck           USA       KF313137
  HA9901               1999             Chicken        China     AY842951
  APC-566              2005             Chicken        USA       DQ387450
  chicken/3337/05      2005             Chicken        Taiwan    FJ439120
  goose/3410/06        2006             Goose          Taiwan    FJ439119
  HLJ07I               2007             Chicken        China     GQ375848
  ZD0708               2007             Chicken        China     FJ496333
  MD-2                 2008             HVT Vaccine    China     JX912710
  HLJR0901             2009             Chicken        China     GQ415646
  1105                 2011             Duck           China     JQ804915
  HA1101               2011             Chicken        China     KF305089
  CY1111               2011             Chicken        China     KJ909531
  GD1210               2012             Chicken        China     KF709431
  SY1209               2012             Chicken        China     KJ909530
  LN1201               2012             Chicken        China     KU641115
  104865               2014             Turkey         USA       KJ756349
  GDBL1401             2014             Pigeon         China     KU204702
  GDBL1402             2014             Pigeon         China     KU204703
  HB2015021            2015             Chicken        China     KY581581
  IBD-C1605            2016             IBDV vaccine   China     KX278301
  SDAUR-S1             2017             Chicken        China     MF185397
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###### 

Reference Marek's disease virus (MDV) strains used for the phylogenetic analysis.

  Strain     Year   Source    Pathotype            Country           GenBank No.
  ---------- ------ --------- -------------------- ----------------- -------------
  Md5        1977   Chicken   Very virulent        USA               NC_002229
  Polen5     2010   Chicken   Very virulent plus   Poland            MF431496
  MD70/13    1970   Chicken   Virulent             Hungary           MF431495
  EU-1       1992   Chicken   Very virulent plus   Italy             MF431494
  GX0101     2001   Chicken   Very virulent        China             JX844666
  814        1986   Chicken   Mild                 China             JF742597
  CU-2       1968   Chicken   Mild                 USA               EU499381
  RB-1B      1981   Chicken   Very virulent        USA               EF523390
  CVI988     1969   Chicken   Mild                 The Netherlands   DQ530348
  ATE2539    2000   Chicken   Very virulent plus   Hungary           MF431493
  LMS        2007   Chicken   Very virulent        China             JQ314003
  GA (att)   1964   Chicken   Virulent             USA               AY129969
  HPRS24     2001   Chicken   vaccine              Japan             NC_002577
  SB-1       1978   Chicken   vaccine              USA               HQ840738
  FC126      1970   Turkey    vaccine              USA               NC_002641
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###### 

The nucleotide and deduced amino acid identities of the USP386 and MDV serotypes.

  Serotype            Nucleotide Identity (%)   Aminoacid Identity (%)                         
  ------------------- ------------------------- ------------------------ ------ ------- ------ ------
  USP386 (MH825642)   99.8--100.0               77.3                     75.5   100.0   91.0   89.6

vetsci-06-00092-t005_Table 5

###### 

The nucleotide and deduced amino acid identities of the USP386 and REV subtypes.

  ----------------------------------------------------------------------------------------------------------------
  Subtype       Nucleotide Identity (%)   Aminoacid Identity (%)                                     
  ------------- ------------------------- ------------------------ ------------- ------ ------------ -------------
  USP386 Pol\   98.9                      97.3--98.0               99.5--100.0   98.9   98.4--98.9   98.9--100.0
  (MH673475)                                                                                         

  USP386 Env\   98.5                      95.40--96.9              99.2--100.0   98.1   96.6--97.6   98.5--100.0
  (MH673476)                                                                                         
  ----------------------------------------------------------------------------------------------------------------
